Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI314 in Ambulatory Patients With COVID-19
NCT05162365Phase 2Terminated
- Sponsor
- Innovent Biologics
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI314 in coronavirus disease 2019 (COVID-19), sponsored by Innovent Biologics. Started Jan 2022; status: terminated.
02
Drugs
IBI314
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05162365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162365.